CCTV+
10.12.2020 10:32:09 CET | Business Wire | Press release
A statement on strengthening media cooperation issued by China Media Group (CMG) and its European media partners, calling on the Chinese and European media to fulfill their responsibilities as public information disseminators and jointly help the international community to gather a strong force to overcome the pandemic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201210005312/en/
CMG and its European media partners issued the statement. /CCTV+
The statement was made during the “2020 European Media Partners Cooperation Online Forum” on December 10, hosted by CMG with the theme of “Mutual Trust Dialogue for Win-Win Cooperation”.
Twenty-eight delegates from 25 organizations in 16 European countries and China had in-depth discussions on how to strengthen coordination, deepen ties, unite to fight the pandemic, and bring greater confidence to the world through in-depth exchanges.
CMG’s President and Editor-in-Chief, Shen Haixiong put forward three proposals on the current media situation. He said, “First, we should deepen cooperation in reporting COVID-19 responses; Second, we should promote the exchange of personnel between the media organizations; Third, we should strengthen the construction of our cooperation mechanism.”
In his speech, he pointed out, China and Europe share a broad consensus and common interests in supporting and practicing multilateralism, strengthening the global response to COVID-19, and jointly promoting global economic recovery and addressing the issue of climate change. We share far more consensus than divergences. Chinese and European media partners will also move towards a new stage of closer, deeper, and more pragmatic dialogue, exchange and cooperation.
Michael Friedenberg, the President of Reuters, said, “We must recognize the power of partnerships in this new media ecosystem. This can take the form of collaborative journalism, industry coalitions, new commercial business opportunities, content-sharing or shared platforms.”
He also mentioned CMG and CCTV+ are important partners and our partnership continues to be a priority.
“Without a clear two-way information communication, there will never be full trust and in-depth cooperation. Therefore, in a friendly relation between different countries and peoples, the media plays a vital role,” said Paolo Panerai, the Editor-in-Chief & CEO of Class Editori S.p.A.’s.
“As global interdependence grows, I believe that media companies cannot work in silos anymore,” Michael Peters, CEO and President of Executive Board of Euronews emphasized. He believes that Euronews and CMG will continue to deepen our collaboration in fostering a better understanding between our cultures.
A launch ceremony of China Business Video (CBV) was also held between CCTV+ and Reuters. It provides Reuters’ customers with financial news content from China, which will be distributed straight by CMG to improve media cooperation between China and other media and to strengthen information exchanges.
At the forum, Teng Yunping, President of CCTV Video News Agency (CCTV+), and Adrian Wells, Managing Director of European News Exchange (ENEX) signed a Strategic Memorandum of Understanding , which signals the official launch of the “European Media Partners (EMP)”. In the future, the two sides will strengthen cooperation on news materials, news reports, overseas reporters, news products, and media forums.
At the same time, the program, BizToday , was released to provide “European Media Partners” with tailored Chinese and European financial news jointly created by CMG, CCTV+ and ENEX.
During the forum, representatives from China and Europe joined an online panel discussion with the theme “Multilateral Cooperation and Mutual Trust, Common Challenges and Win-Win Future” to discuss how the Chinese and European media promote mutual trust between people from both sides and carry out multilateral cooperation to achieve win-win results.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005312/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom